Alcon Buys Aerie Pharma For $770M To Enhance Its Ophthalmic Pharma Portfolio

Alcon Buys Aerie Pharma For $770M To Enhance Its Ophthalmic Pharma Portfolio
  • Alcon AG ALC has agreed to acquire Aerie Pharmaceuticals Inc AERI for $15.25 per share, valuing Aerie at about $770 million.
  • The purchase price represented a premium of 37% to Aerie's last closing price as Alcon looks to bolster its pipeline of ophthalmic treatments.
  • The deal will add Aerie's Rocklatan and Rhopressa eye drops and a pipeline of many clinical and preclinical ophthalmic pharma product candidates to Alcon's portfolio.
  • "Aerie is a natural fit with on-market and pipeline products and R&D capabilities that offer the infrastructure needed to expand our ophthalmic pharmaceutical presence," said Alcon CEO David Endicott
  • Alcon expects the deal to be accretive to its core EPS in 2024 and close in the fourth quarter.
  • Alcon ended the first half of 2022 with a cash position of $1 billion.
  • In May, Alcon acquired Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals Inc KALA for $60 million upfront.
  • In November last year, Alcon acquired U.S. eye-surgery company Ivantis for an initial consideration of $475 million.
  • Price Action: AERI stock is up 33.99% at $14.94, and ALC shares are up 1.21% at $68.76 during the premarket session on the last check Tuesday.

Posted In: BriefsPremarket Moverswhy it's movingLarge CapM&ANewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneral